Mylan has launched Fenofibric Acid Delayed-Release Capsules, 45mg and 135mg, the generic version of AbbVie’s Trilipix Capsules.

Trilipix is indicated as an adjunct to diet in combination with a statin to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal.

It is also indicated as monotherapy to reduce triglycerides in severe hypertriglyceridemia, and to reduce elevated LDL-C, total cholesterol, triglycerides, and Apo B, and to increase HDL-C in primary hyperlipidemia or mixed dyslipidemia.

For more information call (800) RX-MYLAN or visit